+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Keloids Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830061
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 45 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • FirstString Research Inc
  • RXi Pharmaceuticals Corp
  • Sirona Biochem
  • Topadur Pharma AG
  • Yuhan Corp
  • MORE
High levels of pipeline activity are being observed in Keloids treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including FirstString Research Inc, RXi Pharmaceuticals Corp, Topadur Pharma AG, Sirona Biochem, Yuhan Corp and others.

A Significant contribution to the Keloids pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Keloids pipeline included 5 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Keloids condition and increased access to investments is encouraging growth of Keloids drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Keloids drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Keloids therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Keloids pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Keloids. Further, orphan drug status, fast track designation, grants awarded and other special status for Keloids pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Keloids pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Keloids Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Keloids drugs
  • Late phase: Phase 3 and in-approval Keloids drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Keloids therapeutic treatment activities
Details for each Keloids drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Keloids therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • FirstString Research Inc
  • RXi Pharmaceuticals Corp
  • Sirona Biochem
  • Topadur Pharma AG
  • Yuhan Corp
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Keloids- Disease Overview
2.2 Keloids- Pipeline Snapshot
2.3 Keloids- Pipeline Drugs by Phase
2.4 Keloids- Pipeline Drugs by Company
2.5 Keloids- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 FirstString Research Inc Keloids Drug Pipeline, H2- 2019
3.2 RXi Pharmaceuticals Corp Keloids Drug Pipeline, H2- 2019
3.3 Sirona Biochem Keloids Drug Pipeline, H2- 2019
3.4 Topadur Pharma AG Keloids Drug Pipeline, H2- 2019
3.5 Yuhan Corp Keloids Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Keloids- Phase 1 Drug Details
4.2 Keloids- Phase 1 Drug Overview
4.3 Keloids- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Keloids- Phase 2 Drug Details
5.2 Keloids- Phase 2 Drug Overview
5.3 Keloids- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Keloids- Phase 3 Drug Details
6.2 Keloids- Phase 3 Drug Overview
6.3 Keloids- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Keloids- Pre-clinical Phase Drug Details
7.2 Keloids- Pre-clinical Phase Drug Overview
7.3 Keloids- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • FirstString Research Inc
  • RXi Pharmaceuticals Corp
  • Topadur Pharma AG
  • Sirona Biochem
  • Yuhan Corp
Note: Product cover images may vary from those shown
Adroll
adroll